Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Lyall
P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Php295 - Review of Possible Causes of Variation in National Institute for Health and Care Excellence (Nice) Technology Appraisals
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-85 Real-World Gefitinib 1st Line Treatment of Patients With Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-63 Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-Pd1/Pd-L1 Treatment—Data From a Chinese Population
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)
Scientific Reports
Multidisciplinary
P2.01-36 Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in North America: A Systematic Literature Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond
Expert Review of Anticancer Therapy
Oncology
Pharmacology
MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients With Advanced NSCLC Receiving EGFR-TKIs
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-65 First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients With EGFR-Mutant Metastatic NSCLC Receiving TKIs
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary